Acute respiratory distress syndrome, known as ARDS, is a life-threatening form of lung failure in which fluid floods the air sacs of the lungs, making it progressively harder to get oxygen into the bloodstream. It is not a disease you catch; it is a catastrophic inflammatory reaction triggered by another illness or injury, from severe pneumonia to major trauma. Mortality ranges from roughly one in four for mild cases to nearly one in two for the most severe, and survivors often face physical and psychological problems that persist for years.
What ARDS Actually Is
The lungs contain millions of tiny air sacs called alveoli, each wrapped in a mesh of blood vessels. In a healthy lung, oxygen crosses from the air sac into the blood through an extremely thin barrier. ARDS develops when that barrier breaks down. An inflammatory cascade damages both the blood-vessel lining and the air-sac lining, causing protein-rich fluid to leak into the alveoli and effectively drown them from the inside. The result is widespread, rapid-onset difficulty with oxygenation that requires mechanical ventilation in most cases.
This barrier disruption involves two layers of injury. The blood-vessel (endothelial) side and the air-sac (epithelial) side both fail, driven by a storm of inflammatory signaling molecules produced locally in the lung and throughout the body.1PubMed Central. Molecular Mechanisms of Vascular Damage During Lung Injury The fluid that accumulates is not the same as the clear fluid you might see in simple heart failure. It is thick with protein, inflammatory cells, and debris, which makes it much harder to clear and directly interferes with the lung’s natural surfactant, the soap-like coating that keeps alveoli from collapsing.
How Doctors Diagnose It
ARDS is defined by a set of clinical criteria rather than a single lab test. The current standard is the Berlin Definition, published in 2012 by an international panel. It requires four things: the breathing problems must develop within one week of a known trigger or worsening respiratory symptoms; a chest X-ray or CT scan must show white-outs (opacities) on both sides of the lungs; the fluid flooding the lungs cannot be fully explained by heart failure; and the ratio of oxygen in the blood to the concentration of oxygen being delivered by the ventilator must fall below a specific threshold.2PubMed. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material
That oxygen ratio is used to split ARDS into three severity categories: mild, moderate, and severe. In a large patient-level analysis of over 4,000 people, those categories tracked directly with outcomes. Mortality was about 27% in mild ARDS, 32% in moderate, and 45% in severe, and the number of days spent on a ventilator increased with each step.3JAMA. Acute Respiratory Distress Syndrome: The Berlin Definition The grading matters because it guides treatment decisions, particularly whether to escalate to interventions like prone positioning or extracorporeal life support.
What Triggers It
ARDS can be triggered by insults that hit the lungs directly or by problems elsewhere in the body that send a cascade of inflammation to the lungs through the bloodstream. These two pathways, called direct and indirect lung injury, produce overlapping clinical pictures but have distinct biological signatures underneath.4PubMed Central. Clinical and biological heterogeneity in acute respiratory distress syndrome: direct versus indirect lung injury
Direct triggers include pneumonia (by far the most common cause), aspiration of stomach contents into the lungs, inhaling toxic fumes, and near-drowning. In these cases, the damage starts at the air-sac lining. Indirect triggers include sepsis (widespread bloodstream infection), severe pancreatitis, massive blood transfusions, and major trauma. Here, the damage starts on the blood-vessel side.
Studies comparing the two types have found that patients with direct ARDS tend to have higher levels of surfactant protein D, a marker of air-sac injury, while patients with indirect ARDS show more elevated markers of blood-vessel damage and systemic inflammation.5PubMed Central. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies This distinction is more than academic curiosity. Researchers are increasingly interested in whether treatments should be tailored to the injury pathway, rather than treating all ARDS patients identically.
Protective Ventilation Changed Everything
Most people with ARDS need a mechanical ventilator to survive. For decades, the standard approach was to deliver breaths at volumes similar to what a healthy person would breathe naturally. Then, in 2000, a landmark trial run by the ARDS Network changed practice permanently. The trial compared traditional tidal volumes (about 12 mL per kilogram of predicted body weight) to lower volumes (about 6 mL per kilogram). It was stopped early because the low-volume group was clearly doing better: mortality was 31% versus nearly 40%, and patients in the low-volume group spent fewer days on the ventilator.6PubMed. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome
The logic is straightforward. In ARDS, large portions of the lung are flooded and can’t participate in breathing. The remaining functional lung tissue is much smaller than a normal lung, so pushing normal-sized breaths into that reduced space overstretches it and causes additional injury. Smaller breaths protect the surviving lung tissue from further damage. A Cochrane review confirmed a significant reduction in 28-day mortality with lung-protective ventilation.7Cochrane Database of Systematic Reviews. Ventilation with lower tidal volumes as compared with conventional tidal volumes for acute lung injury and the acute respiratory distress syndrome A more recent systematic review pooling 11 studies similarly found roughly a 21% relative reduction in 28-day mortality with low tidal volumes.8PubMed Central. Usefulness of low tidal volume ventilation strategy for patients with acute respiratory distress syndrome: a systematic review and meta-analysis
Low tidal volume ventilation is now the single most established intervention in ARDS care. Despite this, studies continue to show that a concerning fraction of patients in real-world ICUs still receive higher-than-recommended volumes, often because clinicians underrecognize ARDS or prioritize normalizing blood-gas numbers over protecting the lung.
Why Position Matters
Flipping a critically ill, intubated patient face-down sounds counterintuitive, but prone positioning is one of the most effective maneuvers in severe ARDS. In a supine patient, the weight of the swollen, fluid-filled lung compresses the tissue underneath it, collapsing the alveoli in the back of the chest while overdistending those in the front. Turning the patient prone redistributes that weight more evenly, opens up collapsed regions, and improves the match between airflow and blood flow throughout the lung.9PubMed Central. Prone position in ARDS patients: why, when, how and for whom
The strongest evidence comes from the PROSEVA trial, which enrolled patients with severe ARDS and randomized them to prone sessions of at least 16 hours per day or to staying on their backs. The results were striking: 28-day mortality was 16% in the prone group versus about 33% in the supine group, roughly cutting the risk in half.10PubMed. Prone positioning in severe acute respiratory distress syndrome That benefit persisted at 90 days. Not every patient responds equally. A recent prospective study using electrical impedance tomography found that about 60% of patients were classified as “responders” based on improved airflow-blood flow matching. Those responders had significantly lower ICU mortality and more ventilator-free days than non-responders.11PubMed Central. Association between ventilation-perfusion matching improvement during initial prone positioning and ICU mortality in patients with moderate to severe ARDS
Fluid Strategy and Keeping the Lungs Dry
Because the fundamental problem in ARDS is fluid leaking into the lungs, how much intravenous fluid a patient receives matters enormously. A conservative approach, using diuretics to pull fluid out and minimizing IV fluid going in, aims to lower the pressure pushing fluid across those damaged barriers.12PubMed Central. Fluid Management in Acute Respiratory Distress Syndrome
The most influential trial on this question, known as FACTT, compared a conservative fluid strategy to a liberal one in about 1,000 patients with ARDS. Over the first week, the conservative group had an average net fluid balance close to zero, while the liberal group accumulated nearly 7 liters of extra fluid. The conservative group came off the ventilator sooner (about 14.6 ventilator-free days versus 12.1) and left the ICU earlier, without any increase in organ failure or need for dialysis.13PubMed. Comparison of two fluid-management strategies in acute lung injury The overall mortality difference was not statistically significant across the whole group, but a secondary analysis showed that among patients who started with lower central venous pressures, conservative management was associated with substantially lower mortality.14PubMed Central. Impact of Initial Central Venous Pressure on Outcomes of Conservative versus Liberal Fluid Management in Acute Respiratory Distress Syndrome
The tension for clinicians is real. Many ARDS patients also have sepsis or shock, which requires IV fluids to maintain blood pressure. Getting the balance right between keeping the lungs dry and keeping the organs perfused is one of the hardest daily decisions in intensive care.
ECMO as a Last Resort
When the lungs are failing so severely that even optimized ventilator settings, prone positioning, and other measures cannot maintain adequate oxygen levels, extracorporeal membrane oxygenation, or ECMO, becomes an option. ECMO essentially takes over the gas-exchange job of the lungs by pumping blood out of the body, adding oxygen and removing carbon dioxide through a membrane, and returning it to the circulation.
A pooled analysis of individual patient data from two randomized trials found that 90-day mortality was about 36% in patients receiving ECMO compared to 48% in those managed conventionally, a significant reduction.15PubMed Central. ECMO for severe ARDS: systematic review and individual patient data meta-analysis A separate meta-analysis similarly found lower 60-day mortality with ECMO but also flagged a meaningful risk of major bleeding.16The Lancet Respiratory Medicine. Efficacy and safety of venovenous extracorporeal membrane oxygenation in severe acute respiratory distress syndrome
Bleeding is the most common complication, occurring in roughly 30% of ECMO runs, though it directly causes death in a smaller fraction.17PubMed Central. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome Younger patients tend to do better on ECMO, and delays in starting it, measured by the number of days on a conventional ventilator beforehand, are associated with worse outcomes. ECMO is expensive, requires specialized centers, and is not universally available, which makes patient selection and the decision to transfer critically important.
Steroids and the Search for Drug Therapies
Given that ARDS is fundamentally an inflammatory process, corticosteroids seem like a natural fit. The evidence, however, is nuanced. A meta-analysis found that giving steroids to prevent ARDS in at-risk patients appeared, if anything, to increase the odds of developing it. By contrast, giving steroids after ARDS was already established showed a trend toward reduced mortality and significantly increased the number of days off the ventilator by about four days on average.18BMJ. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis The timing distinction is critical: steroids appear harmful before ARDS onset and potentially helpful afterward.
Beyond steroids, no single drug has become a standard treatment for ARDS itself. Surfactant replacement is one of the most studied possibilities. In premature newborns, giving surfactant through the breathing tube is a well-established, life-saving therapy. In adults with ARDS, however, replacement studies have not shown a survival benefit. The reasons likely include the complexity of adult lung injury, the rapid breakdown of replaced surfactant, and the sheer amount of inflammation already present in the alveoli.19PubMed Central. Pulmonary Surfactant in Adult ARDS: Current Perspectives and Future Directions 20PubMed. Exogenous surfactant therapy for ARDS The gap between promise and results in adult surfactant therapy is one of the more frustrating chapters in critical care research.
Hidden Subtypes Within ARDS
One reason so many ARDS drug trials have failed may be that “ARDS” is not one disease but several, grouped together by a shared clinical appearance. Research using clustering algorithms applied to both clinical and biological data has identified at least two distinct subphenotypes across multiple trial cohorts: a “hyperinflammatory” type and a “hypoinflammatory” type. These two groups have different mortality rates and, crucially, respond differently to treatments. In reanalysis of completed trials, what helped one group sometimes hurt the other, with different responses to fluid strategy, ventilator settings, and even simvastatin.21PubMed Central. Phenotypes in acute respiratory distress syndrome: moving towards precision medicine
This is a potential game-changer for how future trials are designed. If past trials enrolled a mixed bag of hyperinflammatory and hypoinflammatory patients, an effective drug could have shown no overall benefit simply because its positive effect in one subgroup was diluted by a neutral or negative effect in the other. Identifying these phenotypes in real time, quickly enough to guide treatment at the bedside, remains the major obstacle. Current classification relies on blood biomarkers that take time to process, which limits their use when decisions need to happen within hours.
COVID-19 and How It Complicated the Picture
The COVID-19 pandemic brought ARDS into public awareness as millions of patients developed severe respiratory failure. Early on, clinicians noticed that some COVID-related ARDS cases behaved differently from the “classic” form. Many COVID patients had severely low oxygen levels despite relatively preserved lung compliance, meaning their lungs were still stretchy even though oxygenation was terrible. A study matching COVID-ARDS patients to those with typical ARDS found that in classic ARDS, the degree of oxygen impairment correlated tightly with how much lung tissue was collapsed. In COVID-ARDS, that correlation did not hold, suggesting that the oxygen problems were driven less by collapsed tissue and more by disrupted blood flow within the lung.22PubMed Central. Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study
This observation fueled debate about whether COVID-ARDS was truly a different entity or simply one end of the spectrum. The practical impact was significant. Some clinicians argued for higher ventilator volumes in COVID patients because their lungs were more compliant, while others stuck to the established lung-protective strategy. By now, the consensus has largely settled back toward standard ARDS protocols, but the pandemic underscored how much heterogeneity hides under a single diagnosis.
Life After ARDS
Surviving ARDS is only part of the battle. Between six months and two years after ICU discharge, survivors commonly report significant weakness, reduced walking capacity, and lower physical quality of life. The psychological toll is at least as severe: roughly a quarter to a third of survivors experience depression, close to 40% struggle with anxiety, and about one in four develop post-traumatic stress disorder.23PubMed Central. Long-term outcome after the acute respiratory distress syndrome: different from general critical illness? These impairments can linger for five years or more and often do not fully resolve.24British Journal of Anaesthesia. Physical and psychological impairment in survivors of acute respiratory distress syndrome: a systematic review and meta-analysis
Cognitive problems, including trouble with memory, attention, and executive function, add another layer.25PubMed Central. Long-Term Outcomes in Acute Respiratory Distress Syndrome: Epidemiology, Mechanisms, and Patient Evaluation The combination of physical, cognitive, and mental health challenges can make returning to work difficult and strain relationships. Post-ICU rehabilitation programs and follow-up clinics have grown in number since the COVID era, but access remains uneven and many survivors are essentially left to figure out recovery on their own.
ARDS in Children
For years, children with severe respiratory failure were diagnosed and treated using criteria designed for adults. That changed with the development of pediatric-specific definitions and guidelines, most recently updated in the PALICC-2 recommendations. Pediatric ARDS uses different oxygen metrics than the adult Berlin Definition, because pulse oximetry is used more often in children than arterial blood gas sampling, and the thresholds for severity categories are adjusted accordingly. Children must also be observed for at least four hours before being classified into a severity category, to avoid capturing transient respiratory problems.26PubMed Central. Executive Summary of the Second International Guidelines for the Diagnosis and Management of Pediatric Acute Respiratory Distress Syndrome (PALICC-2)
Outcomes in pediatric ARDS are generally better than in adults, partly because children have fewer underlying diseases and greater physiological reserve. Still, the sickest children face real mortality risk, and the same principles of lung-protective ventilation and careful fluid management apply.
Biomarkers and Machine Learning
One of the frustrations with ARDS is that it is still diagnosed by clinical criteria and a chest X-ray, tools that are subjective and often lead to underdiagnosis or delayed recognition. Researchers are working on two fronts to improve this.
On the biomarker side, a systematic review of lung fluid samples found that markers of inflammation, blood-vessel injury, air-sac injury, and abnormal clotting were all elevated in ARDS patients. Among these, markers of air-sac damage, particularly surfactant protein D and sRAGE, showed the strongest and most consistent association with the amount of fluid in the lungs, suggesting that epithelial injury may be the final common pathway through which the alveolar barrier fails.27PubMed Central. Biomarkers of alveolar epithelial injury and endothelial dysfunction are associated with scores of pulmonary edema in invasively ventilated patients 28PubMed Central. Lung fluid biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis These biomarkers are not yet used routinely at the bedside, but they are becoming central to clinical trial design and subphenotype identification.
On the computational side, machine learning algorithms trained on electronic health record data, including vital signs, lab results, and imaging, can flag patients at risk for developing ARDS before it becomes clinically obvious. One model achieved strong performance for detecting ARDS at onset and remained useful when predicting ARDS 12 to 48 hours in advance.29PubMed. Supervised machine learning for the early prediction of acute respiratory distress syndrome (ARDS) Earlier recognition could allow clinicians to start protective ventilation strategies sooner, potentially preventing the full syndrome from developing in some patients.
Stem Cell Therapies on the Horizon
Mesenchymal stem cells, harvested from sources like bone marrow, fat tissue, or umbilical cord, have attracted interest because they seem to address several problems in ARDS at once. In preclinical models, they reduce inflammation, modulate the immune response, promote tissue repair, and even transfer healthy mitochondria to damaged cells.30PubMed Central. Mesenchymal stem cell therapies for ARDS: translational promise and challenges Animal studies have shown improvements in lung structure, reduced fluid accumulation, and fewer infiltrating immune cells in treated animals compared to controls.31Signal Transduction and Targeted Therapy. Mesenchymal stromal cells alleviate acute respiratory distress syndrome through the cholinergic anti-inflammatory pathway
Human trials to date have focused mainly on safety and are still small. The gap between dramatic preclinical results and clinical proof of benefit is a familiar story in ARDS research, echoing the surfactant experience. Challenges include determining the optimal cell source, dose, and timing, as well as the fact that ARDS patients are extremely heterogeneous. Whether stem cell therapy will eventually join the ARDS toolkit or follow other promising therapies into the graveyard of “worked in mice, didn’t pan out in humans” remains to be seen.32PubMed. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential